Compugen (NASDAQ:CGEN) Now Covered by Lake Street Capital

Lake Street Capital began coverage on shares of Compugen (NASDAQ:CGEN) in a research note released on Tuesday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $6.00 price objective on the biotechnology company’s stock.

A number of other equities analysts also recently issued reports on CGEN. HC Wainwright initiated coverage on Compugen in a research report on Wednesday, January 7th. They set a “buy” rating and a $4.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Compugen in a research report on Wednesday, January 21st. Wall Street Zen raised Compugen from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Finally, Truist Financial raised Compugen to a “strong-buy” rating in a research report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $5.00.

Compugen Trading Up 6.4%

Shares of CGEN stock opened at $2.32 on Tuesday. The business’s fifty day simple moving average is $1.97 and its 200-day simple moving average is $1.79. The company has a market cap of $219.36 million, a PE ratio of 6.27 and a beta of 2.77. Compugen has a 12-month low of $1.13 and a 12-month high of $2.38.

Compugen (NASDAQ:CGEN) last issued its quarterly earnings results on Monday, March 2nd. The biotechnology company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.55. The business had revenue of $67.33 million for the quarter, compared to the consensus estimate of $14.30 million. Compugen had a return on equity of 55.68% and a net margin of 48.57%. On average, equities analysts forecast that Compugen will post -0.03 earnings per share for the current year.

Institutional Investors Weigh In On Compugen

Several hedge funds have recently added to or reduced their stakes in CGEN. Bank Hapoalim BM purchased a new stake in Compugen in the fourth quarter valued at $37,000. Security National Bank of Sioux City Iowa IA purchased a new stake in Compugen in the fourth quarter valued at $38,000. Franklin Resources Inc. purchased a new stake in Compugen in the second quarter valued at $56,000. Osaic Holdings Inc. boosted its holdings in Compugen by 346.0% in the second quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 34,045 shares during the last quarter. Finally, WINTON GROUP Ltd purchased a new stake in Compugen in the fourth quarter valued at $84,000. 12.22% of the stock is owned by hedge funds and other institutional investors.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.